Bright Minds Biosciences (DRUG) AI Stock Analysis

Bright Minds Biosciences

(NASDAQ:DRUG)

Select Model

Rating:45Neutral

Price Target:$51.00▼(-7.24% Downside)

Action:reiterated

Date:10/08/26

Overall score reflects heavy financial drag from no revenue, widening losses, and accelerating cash burn, partially offset by a very low-debt balance sheet and strengthened equity base. Technicals further weigh on the score with the stock trading below all key moving averages and negative MACD alongside very weak momentum. Valuation is constrained by negative earnings and no dividend yield.

Positive Factors

Very low leverageExtremely low debt reduces refinancing pressure and fixed financial obligations while preserving flexibility to direct capital toward research and development. This gives Bright Minds a less leveraged balance sheet than many development-stage companies, although it does not eliminate the need to fund ongoing losses.

Negative Factors

No operating revenueWith no reported product revenue, Bright Minds lacks an operating base to fund research, clinical trials, or corporate costs internally. The business therefore remains dependent on financing or future partnering and commercialization success, making execution and access to capital central to its medium-term outlook.

Bright Minds Biosciences (DRUG) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $759.53M
Dividend Yield: ―
Average Volume (3M): 127.86K
Price to Earnings (P/E): -26.6
Beta (1Y): 0.92
Revenue Growth: ―
EPS Growth: -120.28%
Country: US
Employees: 26
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Bright Minds Biosciences Business Overview & Revenue Model

Company Description

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...

How the Company Makes Money

Bright Minds Biosciences does not have publicly known recurring revenue from marketed products; therefore, revenue from product sales is null. As a clinical-stage biotech, the company’s ability to generate cash has primarily been tied to financing ac...

Bright Minds Biosciences Financial Statement Overview

Summary

Mixed financial profile. Income statement is weak with no revenue and widening losses (TTM net loss ~$24.7M; EBIT deeply negative), and cash flow is also weak with accelerating cash burn (TTM operating cash flow ~-$25.0M). The balance sheet is the key offset with extremely low debt and a much larger equity base in the latest period, supporting funding flexibility despite negative returns on equity.

Income Statement

12Very Negative

Balance Sheet

72Positive

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Sep 2025	Dec 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-40.10K	0	0	0	0	0
EBITDA	-33.94M	-12.15M	-2.73M	-7.30M	-14.96M	-27.64K
Net Income	-24.75M	-12.23M	-2.80M	-7.37M	-14.96M	-8.65M
Balance Sheet
Total Assets	310.84M	84.42M	6.10M	6.88M	12.09M	20.04M
Cash, Cash Equivalents and Short-Term Investments	308.33M	82.91M	5.72M	6.75M	11.63M	19.76M
Total Debt	65.70K	125.78K	118.96K	73.55K	139.91K	0
Total Liabilities	2.55M	2.38M	568.26K	280.86K	1.54M	638.57K
Stockholders Equity	308.30M	82.04M	5.54M	6.60M	10.54M	19.40M
Cash Flow
Free Cash Flow	-25.00M	-8.69M	-1.85M	-7.02M	-13.59M	-7.32M
Operating Cash Flow	-25.00M	-8.69M	-1.85M	-7.02M	-13.59M	-7.32M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	277.00M	85.57M	810.57K	2.19M	5.20M	26.06M

Bright Minds Biosciences Technical Analysis

Technical Analysis SentimentNeutral

Last Price54.98

Price Trends

50DMA59.18Negative

100DMA65.59Negative

200DMA73.27Negative

Market Momentum

MACD-0.87Negative

RSI50.30Neutral

STOCH59.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRUG, the sentiment is Neutral. The current price of 54.98 is above the 20-day moving average (MA) of 52.72, below the 50-day MA of 59.18, and below the 200-day MA of 73.27, indicating a neutral trend. The MACD of -0.87 indicates Negative momentum. The RSI at 50.30 is Neutral, neither overbought nor oversold. The STOCH value of 59.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DRUG.

Bright Minds Biosciences Risk Analysis

Bright Minds Biosciences disclosed 26 risk factors in its most recent earnings report. Bright Minds Biosciences reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Bright Minds Biosciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DRUG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRUG	45Neutral	$542.33M	-26.55	-12.56%	―	―	-120.28%

* Healthcare Sector Average

Performance Comparison

DRUG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DRUG	Bright Minds Biosciences Inc.	54.98	3.52	6.84%
TSE:MYND	Mynd Life Sciences Inc	0.07	0.00	0.00%
TSE:IBO	Universal Ibogaine Inc	0.01	0.00	0.00%
TSE:MBIO	Mindbio Therapeutics Corp.	0.10	-1.90	-94.75%

Bright Minds Biosciences Corporate Events

Bright Minds Biosciences Shareholders Back Board and Auditor at March 2026 AGM

Oct 2, 2026

Bright Minds Biosciences reported the voting results from its annual general meeting of shareholders held on March 31, 2026, where 7,877,637 common shares were cast, representing 80.49% of outstanding shares. Shareholders strongly supported the compa...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

Bright Minds Biosciences AI Stock Analysis